Clinical TrialsScholar Rock recently announced highly compelling top line results from its Phase 2 EMBRAZE trial, reinforcing the clinical potential of apitegromab when used in combination with tirzepatide in obese and overweight patients.
Safety ProfileThe safety and tolerability of the apitegromab combination were highly favorable and well aligned with prior studies, with no serious adverse events attributed to apitegromab.
Strategic FocusScholar Rock's decision to prioritize neuromuscular rare disease development is viewed as a savvy decision, avoiding more significant competition in obesity with large Pharma.